|
Kravchenko A.V., Orlova-Morozova E.A., Shimonova T.E., Kozyrev O.A., Nagimova F.I., Bychko V.V., Vostokova N.V., Zozulya O.V.
The efficacy and safety of a new Russian HIV non-nucleoside reverse transcriptase inhibitor (VM-1500, Elpivirine) as a component in an antiretroviral therapy regimen
|
№5 / 2015
|
|
Kravchenko A.V.
Antiretroviral therapy regimens containing the HIV protease inhibitor saquinavir
|
№3 / 2015
|
|
Kravchenko A.V., Kanestri V.G., Gankina N.Yu.
Efficacy and safety of antiretroviral therapy regimens containing etravirine for HIV-infected patients
|
№2 / 2015
|
|
Kanestri V.G., Kravchenko A.V., Gankina N.Yu.
Hepatotoxicity of antiretroviral therapy in HIV-infected patients
|
№1 / 2015
|
|
Yurin O.G., Kravchenko A.V., Kanestri V.G., Pokrovskaya A.V., Shakhgildyan V.I., Volkova S.B.
Dual antiretroviral therapy with lopinavir and ritonavir
|
№6 / 2014
|
|
Kozyrina N.V., Narsia R.S., Yurin O.G.
Abacavir and lamivudine as a nucleoside base of antiretroviral therapy
|
№5 / 2014
|
|
Mikova O.E., Moiseeva G.V.
Use of a combination of the antiretroviral drugs darunavir® and etravirine® in a patient with a resistant HIV strain
|
№4 / 2014
|
|
Moskvicheva M.G., Radzikhovskaya M.V.
Experience with the HIV protease inhibitor fosamprenavir in first-line antiretroviral therapy regimens in the Chelyabinsk Region
|
№3 / 2014
|
|
Khasanova G.R.
Lipodystrophy syndrome in patients with HIV infection
|
№3 / 2014
|
|
Beketova E.V., Bykov S.A.
Experience with enfuvirtide (fuzeon) in the treatment regimens for HIV infection
|
№2 / 2014
|
|
Kanestri V.G.
Contribution of a fixed-dose abacavir/lamivudine combination to improving treatment compliance in HIV-infected patients
|
№6 / 2013
|
|
Gushchina Yu.Sh., Kubaeva M. B.
Prospects for the long-term efficaсay of fosamprenavir (telzir) used as part of antiretroviral therapy in hiv-infected patients
|
№6 / 2013
|
Русский
